How will you mitigate the risk in IPF drug development?

In idiopathic pulmonary fibrosis (IPF), a chronic and progressive restrictive lung disease, a decline in forced vital capacity (FVC) is used as a primary endpoint in clinical trial. As IPF is a restrictive lung disease, lung diffusion measurements like DLCO and TLCO are needed to monitor drug efficacy. The importance of accurate data collection is critical to demonstrating drug effectiveness in clinical trial.




ACHIEVE THE HIGHEST DATA QUALITY AND REDUCE VARIABILITY

ERT has partnered with sponsors in over 1000 drug development studies. Our lung function testing devices, workflow-driven software, and quality services ensure your trial’s spirometry quality and overall site performance and mitigates the risks in IPF drug development. ERT offers an integrated solution to measure lung function endpoints, using integrated devices and software to measure FVC.

Experts in Respiratory Solutions


3 Strategies to Capture Respiratory Data

e-Book

3 Strategies to Capture Respiratory Data

This quick guide gives you strategies and tips you need to collect high-quality data and get compounds to market faster.


LEARN MORE ABOUT HOW ERT CAN SUPPORT YOUR CLINICAL TRIAL with an integrated solution


SPIROMETRY

measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled, includes FVC, FEV1, and PEF.

SITE SUPPORT:

HOME SUPPORT:

LCI

(Lung Clearance Index) measured by multiple breath washout is a sensitive measure of ventilation inhomogeneity.

SUPPORTED DEVICES

DLCO

(Diffusing Capacity for CO) measures the lung’s ability to transfer gas from inhaled air to the red blood cells.

SUPPORTED DEVICES

eCOA

Collects respiratory patient questionnaires for real-time insights into patient safety and study performance.

Learn More

Cardiac Safety

Captures, reads, and stores ECGs centrally to avoid the risk of false or inaccurate data.

Learn More

Imaging

Measures and analyzes imaging endpoints like chest computed tomography (CT) to provide on-demand evidence of drug safety and efficacy.

Learn More

ASTHMA Trials

Asthma Trials

Capture pulmonary function test data along with symptoms of asthma exacerbations, like breathlessness, chest pain, cough, and wheezing to help improve patients’ quality of life. ERT’s integrated solution will ensure you are collecting acceptable data for your study’s regulatory submissions.

Learn More

COPD Trials

COPD Trials

Demonstrate your Chronic Obstructive Pulmonary Disease (COPD) study’s efficacy in improving lung function and quality of life symptoms with improved data acceptability and exacerbation event capture. ERT’s respiratory solution helps you meet your study goals.

Learn More

Cystic Fibrosis Trials

Cystic Fibrosis Trials

Identify the right endpoints for your complex cystic fibrosis (CF) trials. ERT has solutions that measure multiple lung function parameters and can be integrated with other endpoint measurement data solutions.

Learn More


Disease Progression Trials

Lung Safety and Disease Progression Trials

Because decline in respiratory function is a direct result of progression of certain non-pulmonary diseases, demonstrating a treatment benefit on respiratory endpoints may provide evidence of your drug’s effectiveness. ERT enables precise lung function testing integrated with other efficacy data points like patient-reported outcomes (PRO) and more.

Learn More

Home Spirometry

Home Spirometry

Spirometry collection at home, by patient, or with home nurse integrates with other ERT at-home solutions to keep patients safe and studies on track.

Learn More

RESOURCES


Talk to a Specialist


Our team of experts is available to address questions you may have about our integrated respiratory solutions. Submit your contact information and we’ll be in touch shortly.